O-0023 Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC)

Alberto F. Sobrero(Ospedale Policlinico San Martino), Dirk Laurent(Menarini Group (Germany)), Marc Ychou(Université de Montpellier), Josep Tabernero(Deaconess Hospital), Daniel J. Sargent(National Institute of Agricultural Botany), Antoine Adenis(Inserm), Salvatore Siena(University of Milan), Y. Humblet(UCLouvain Saint-Louis Brussels), Axel Grothey(Campbell Clinic), Takayuki Yoshino(University of Tsukuba), Laurent Mineur(Institut Sainte Catherine), Olivier Bouché(CHU Dijon Bourgogne), Richard M. Goldberg(Ontario Institute for Cancer Research), Frank Cihon(Alleanza Contro il Cancro), Eric Van Cutsem(Universitair Ziekenhuis Leuven), H. Lenz(University of Southern California), Alfredo Falcone(Azienda Ospedaliero-Universitaria Careggi), Michael Jeffers(Sepragen Corporation (United States)), Carlo Barone(Università Cattolica del Sacro Cuore)
Annals of Oncology
June 1, 2012
10.1016/s0923-7534(19)66487-2
Cited by 2

Related Papers

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
|Science|2017|6.6k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k